Price movement over the last 24 hours
Automatic Data Processing Inc vs ResMed Inc. — how do they compare? Automatic Data Processing Inc trades at $241.96 (market cap $98.17B), while ResMed Inc. trades at $208.95 (market cap $31.88B). The key difference: Automatic Data Processing Inc is far larger — about 3.1× ResMed Inc.'s market cap, and Automatic Data Processing Inc pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| ADP | RMD | |
|---|---|---|
Market Cap | $98.17B | $31.88B |
Sector | Industrials | Health |
52-Week High | $310.94 | $293.73 |
52-Week Low | $188.79 | $182.82 |
Enterprise Value | $99.24B | $31.06B |
Dividend Yield | 2.77% | 1.09% |
Signals from Pluang's Aura AI — not financial advice
ADP trades at $245.60, up 1.37% on the day, near its 52-week high. The stock shows bullish technical signals with consistent earnings beats in recent quarters. Revenue grew to $20.56 billion in 2025, with a net income margin of 20.12%. Analyst sentiment is mixed, with a consensus hold rating but a technical outlook suggesting strength. The company maintains strong profitability metrics and recently announced a dividend payment.
Outlook remains stable with projected revenue growth to $21.6 billion in 2026. Risks include competitive pressures and economic sensitivity. Opportunities lie in AI integration and margin expansion. The stock offers value through dividends and steady performance, though valuation multiples are elevated relative to historical averages.
ResMed (RMD) trades at $219.75, up 4.83% on the day, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The company reported robust fundamentals with 2025 revenue of $5.15B and net income of $1.40B, supported by a 27.44% net margin. Recent strategic moves include the sale of MatrixCare for $490M and the acquisition of Noctrix Health, sharpening focus on core sleep and respiratory care markets.
Outlook remains positive with a consensus price target of $267.33 implying 21.6% upside, though risks include competitive pressures and integration challenges from recent M&A. The stock's current valuation at 21.06 P/E appears reasonable given growth prospects, but investors should monitor execution on guidance and market share retention amid emerging threats like GLP-1 drugs.
Trailing returns across standard periods
Latest headlines on both assets
ADP is a provider of payroll and human capital management solutions servicing the full scope of businesses from micro to global enterprises. ADP was established in 1949 and serves over 990,000 clients primarily in the United States. ADP's employer services segment offers payroll, HCM solutions, HR outsourcing, insurance and retirement services. The smaller but faster-growing PEO segment provides HR outsourcing solutions to small and midsize businesses through a co-employment model.
Read more on ADP →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →